These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30715419)

  • 1. Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study.
    Hescot S; Curras-Freixes M; Deutschbein T; van Berkel A; Vezzosi D; Amar L; de la Fouchardière C; Valdes N; Riccardi F; Do Cao C; Bertherat J; Goichot B; Beuschlein F; Drui D; Canu L; Niccoli P; Laboureau S; Tabarin A; Leboulleux S; Calsina B; Libé R; Faggiano A; Schlumberger M; Borson-Chazot F; Mannelli M; Gimenez-Roqueplo AP; Caron P; Timmers HJLM; Fassnacht M; Robledo M; Borget I; Baudin E;
    J Clin Endocrinol Metab; 2019 Jun; 104(6):2367-2374. PubMed ID: 30715419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
    Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
    Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
    Assadipour Y; Sadowski SM; Alimchandani M; Quezado M; Steinberg SM; Nilubol N; Patel D; Prodanov T; Pacak K; Kebebew E
    Surgery; 2017 Jan; 161(1):230-239. PubMed ID: 27839933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in Clinical Manifestations and Tumor Features Between Metastatic Pheochromocytoma/Paraganglioma Patients With and Without Germline SDHB Mutation.
    Cui Y; Ma X; Wang F; Wang H; Zhou T; Chen S; Tong A; Li Y
    Endocr Pract; 2021 Apr; 27(4):348-353. PubMed ID: 34024343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas.
    Amar L; Baudin E; Burnichon N; Peyrard S; Silvera S; Bertherat J; Bertagna X; Schlumberger M; Jeunemaitre X; Gimenez-Roqueplo AP; Plouin PF
    J Clin Endocrinol Metab; 2007 Oct; 92(10):3822-8. PubMed ID: 17652212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
    Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
    Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma.
    Hescot S; Leboulleux S; Amar L; Vezzosi D; Borget I; Bournaud-Salinas C; de la Fouchardiere C; Libé R; Do Cao C; Niccoli P; Tabarin A; Raingeard I; Chougnet C; Giraud S; Gimenez-Roqueplo AP; Young J; Borson-Chazot F; Bertherat J; Wemeau JL; Bertagna X; Plouin PF; Schlumberger M; Baudin E;
    J Clin Endocrinol Metab; 2013 Oct; 98(10):4006-12. PubMed ID: 23884775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes.
    Benn DE; Gimenez-Roqueplo AP; Reilly JR; Bertherat J; Burgess J; Byth K; Croxson M; Dahia PL; Elston M; Gimm O; Henley D; Herman P; Murday V; Niccoli-Sire P; Pasieka JL; Rohmer V; Tucker K; Jeunemaitre X; Marsh DJ; Plouin PF; Robinson BG
    J Clin Endocrinol Metab; 2006 Mar; 91(3):827-36. PubMed ID: 16317055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation analysis of SDHB and SDHC: novel germline mutations in sporadic head and neck paraganglioma and familial paraganglioma and/or pheochromocytoma.
    Bayley JP; van Minderhout I; Weiss MM; Jansen JC; Oomen PH; Menko FH; Pasini B; Ferrando B; Wong N; Alpert LC; Williams R; Blair E; Devilee P; Taschner PE
    BMC Med Genet; 2006 Jan; 7():1. PubMed ID: 16405730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The penetrance of paraganglioma and pheochromocytoma in SDHB germline mutation carriers.
    Rijken JA; Niemeijer ND; Jonker MA; Eijkelenkamp K; Jansen JC; van Berkel A; Timmers HJLM; Kunst HPM; Bisschop PHLT; Kerstens MN; Dreijerink KMA; van Dooren MF; van der Horst-Schrivers ANA; Hes FJ; Leemans CR; Corssmit EPM; Hensen EF
    Clin Genet; 2018 Jan; 93(1):60-66. PubMed ID: 28503760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature.
    Tong A; Li M; Cui Y; Ma X; Wang H; Li Y
    Front Endocrinol (Lausanne); 2020; 11():61. PubMed ID: 32132978
    [No Abstract]   [Full Text] [Related]  

  • 12. Positive Impact of Genetic Test on the Management and Outcome of Patients With Paraganglioma and/or Pheochromocytoma.
    Buffet A; Ben Aim L; Leboulleux S; Drui D; Vezzosi D; Libé R; Ajzenberg C; Bernardeschi D; Cariou B; Chabolle F; Chabre O; Darrouzet V; Delemer B; Desailloud R; Goichot B; Esvant A; Offredo L; Herman P; Laboureau S; Lefebvre H; Pierre P; Raingeard I; Reznik Y; Sadoul JL; Hadoux J; Tabarin A; Tauveron I; Zenaty D; Favier J; Bertherat J; Baudin E; Amar L; Gimenez-Roqueplo AP;
    J Clin Endocrinol Metab; 2019 Apr; 104(4):1109-1118. PubMed ID: 30698717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Predictors of Malignancy in Patients with Pheochromocytoma and Paraganglioma.
    Dhir M; Li W; Hogg ME; Bartlett DL; Carty SE; McCoy KL; Challinor SM; Yip L
    Ann Surg Oncol; 2017 Nov; 24(12):3624-3630. PubMed ID: 28884434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
    van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
    J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.
    Hamidi O; Young WF; Iñiguez-Ariza NM; Kittah NE; Gruber L; Bancos C; Tamhane S; Bancos I
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3296-3305. PubMed ID: 28605453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas.
    Timmers HJ; Kozupa A; Eisenhofer G; Raygada M; Adams KT; Solis D; Lenders JW; Pacak K
    J Clin Endocrinol Metab; 2007 Mar; 92(3):779-86. PubMed ID: 17200167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations.
    Jochmanova I; Wolf KI; King KS; Nambuba J; Wesley R; Martucci V; Raygada M; Adams KT; Prodanov T; Fojo AT; Lazurova I; Pacak K
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1421-1435. PubMed ID: 28374168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The phenotype of
    Niemeijer ND; Rijken JA; Eijkelenkamp K; van der Horst-Schrivers ANA; Kerstens MN; Tops CMJ; van Berkel A; Timmers HJLM; Kunst HPM; Leemans CR; Bisschop PH; Dreijerink KMA; van Dooren MF; Bayley JP; Pereira AM; Jansen JC; Hes FJ; Hensen EF; Corssmit EPM
    Eur J Endocrinol; 2017 Aug; 177(2):115-125. PubMed ID: 28490599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators.
    Gimenez-Roqueplo AP; Caumont-Prim A; Houzard C; Hignette C; Hernigou A; Halimi P; Niccoli P; Leboulleux S; Amar L; Borson-Chazot F; Cardot-Bauters C; Delemer B; Chabolle F; Coupier I; Libé R; Peitzsch M; Peyrard S; Tenenbaum F; Plouin PF; Chatellier G; Rohmer V
    J Clin Endocrinol Metab; 2013 Jan; 98(1):E162-73. PubMed ID: 23162105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation analysis of the SDHB and SDHD genes in pheochromocytomas and paragangliomas: identification of a novel nonsense mutation (Q168X) in the SDHB gene.
    Oishi Y; Nagai S; Yoshida M; Fujisawa S; Sazawa A; Shinohara N; Nonomura K; Matsuno K; Shimizu C
    Endocr J; 2010; 57(8):745-50. PubMed ID: 20505258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.